Anél Petzer et al., 2011-12-16: Recombinant human MAO study giving the potency numbers: methylene blue inhibits MAO-A with an IC50 of 70 nM, and its demethylated metabolite azure B with an IC50 of 11 nM; MAO-B inhibition is far weaker.
azure B is a potent MAO-A inhibitor (IC₅₀=11 nM), approximately 6-fold more potent than is MB (IC₅₀=70 nM) under identical conditions.
Abstract
Anél Petzer et al., 2011-12-16: Recombinant human MAO study giving the potency numbers: methylene blue inhibits MAO-A with an IC50 of 70 nM, and its demethylated metabolite azure B with an IC50 of 11 nM; MAO-B inhibition is far weaker. Laboratory enzymology with recombinant human MAO-A and MAO-B (no subjects). Country: South Africa (North-West University) with a Danish co-author. Concentrations: IC50 70 nM (MB, MAO-A), 11 nM (azure B, MAO-A), 968 nM (azure B, MAO-B). Route: in vitro. Funder: 'Research Support, Non-U.S. Gov't' (South African National Research Foundation and others; see paper). Conflicts: none declared in the record. Comparator: untreated enzyme, reference inhibitors. Bearing note: gives the concrete potency figures C4 asks for, and adds a wrinkle – the major metabolite is about six times more potent than the parent drug, so measured MAO inhibition in vivo reflects both. Study type: lab.
